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ABSTRACT
Objective Delayed second dose SARS- CoV-2 vaccination 
trades maximal effectiveness for a lower level of immunity 
across more of the population. We investigated whether 
patients with inflammatory bowel disease treated with 
infliximab have attenuated serological responses to a single 
dose of a SARS- CoV-2 vaccine.
Design Antibody responses and seroconversion rates 
in infliximab- treated patients (n=865) were compared 
with a cohort treated with vedolizumab (n=428), a gut- 
selective anti- integrin α4β7 monoclonal antibody. Our 
primary outcome was anti- SARS- CoV-2 spike (S) antibody 
concentrations, measured using the Elecsys anti- SARS- CoV-2 
spike (S) antibody assay 3–10 weeks after vaccination, 
in patients without evidence of prior infection. Secondary 
outcomes were seroconversion rates (defined by a cut- off of 
15 U/mL), and antibody responses following past infection or 
a second dose of the BNT162b2 vaccine.
Results Geometric mean (SD) anti- SARS- CoV-2 antibody 
concentrations were lower in patients treated with infliximab 
than vedolizumab, following BNT162b2 (6.0 U/mL (5.9) vs 
28.8 U/mL (5.4) p<0.0001) and ChAdOx1 nCoV-19 (4.7 U/
mL (4.9)) vs 13.8 U/mL (5.9) p<0.0001) vaccines. In our 
multivariable models, antibody concentrations were lower 
in infliximab- treated compared with vedolizumab- treated 
patients who received the BNT162b2 (fold change (FC) 0.29 
(95% CI 0.21 to 0.40), p<0.0001) and ChAdOx1 nCoV-19 
(FC 0.39 (95% CI 0.30 to 0.51), p<0.0001) vaccines. In 
both models, age ≥60 years, immunomodulator use, Crohn’s 
disease and smoking were associated with lower, while non- 
white ethnicity was associated with higher, anti- SARS- CoV-2 
antibody concentrations. Seroconversion rates after a single 
dose of either vaccine were higher in patients with prior 
SARS- CoV-2 infection and after two doses of BNT162b2 
vaccine.
Conclusion Infliximab is associated with attenuated 
immunogenicity to a single dose of the BNT162b2 and 
ChAdOx1 nCoV-19 SARS- CoV-2 vaccines. Vaccination 
after SARS- CoV-2 infection, or a second dose of vaccine, 
led to seroconversion in most patients. Delayed second 
dosing should be avoided in patients treated with 
infliximab.
Trial registration number ISRCTN45176516.
INTRODUCTION
Limited SARS- CoV-2 vaccine supplies and pressure 
on critical care services have forced governments to 
prioritise primary vaccination to vulnerable groups. 
Significance of this study
What is already known on this subject?
 ► A growing number of countries, including the 
UK, have opted to delay second SARS- CoV-2 
vaccine doses for all people, trading maximal 
effectiveness against a lower level of protective 
immunity across more of the at- risk population. 
Whether single doses of vaccines are effective 
in patients treated with antitumour necrosis 
factor (TNF) therapies is unknown.
 ► We have previously shown in this cohort 
that seroprevalence, seroconversion in PCR- 
confirmed cases and the magnitude of anti- 
SARS- CoV-2 antibodies following SARS- CoV-2 
infection are reduced in infliximab- treated 
compared with vedolizumab- treated patients.
 ► Two recent studies have reported that SARS- 
CoV-2 spike (S) antibody responses are 
impaired in patients with cancer and transplant 
recipients treated with chemotherapy 
and antimetabolite immunosuppressants, 
respectively. To date, no studies have 
assessed the effect of anti- TNF therapy 
on immunogenicity following SARS- CoV-2 
vaccination.
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In the UK, second vaccine doses have also been delayed, trading 
maximal effectiveness for a lower level of protective immunity 
across a greater proportion of the most at- risk population.1 
Consequently, more than half of the adult population have 
received a single dose of either the RNA vaccine, BNT162b2 
(Pfizer/BioNTech) or the adenovirus- vector vaccine, ChAdOx1 
nCoV-19 (Oxford/AstraZeneca). Faced with further surges of 
SARS- CoV-2 infection, a growing number of other countries 
have also opted to delay second vaccine doses.2 3
The inflammatory bowel diseases (IBD), Crohn’s disease and 
ulcerative colitis (UC) are chronic immune- mediated inflamma-
tory diseases (IMIDs) that affect about 1% of the UK popula-
tion.4 5 Treatment typically requires immunosuppression with 
immunomodulators (azathioprine, mercaptopurine and metho-
trexate) and/or biological therapies that target disease relevant 
cytokines or the immune cells that produce them. Antitumour 
necrosis factor (TNF) drugs, such as infliximab and adalimumab, 
are the most frequently prescribed biopharmaceuticals used in 
the treatment of IMIDs. These drugs impair immunogenicity 
following pneumococcal,6 influenza7 and hepatitis B8 vaccina-
tions and increase the risk of serious infection, most notably with 
respiratory pathogens.9 Conversely, vedolizumab, a gut- selective 
anti- integrin α4β7 monoclonal antibody, is not associated with 
increased susceptibility to systemic infection or attenuated sero-
logical responses to vaccination.10
We have recently reported that seroprevalence, serocon-
version in PCR- confirmed cases, and the magnitude of anti- 
SARS- CoV-2 antibodies following SARS- CoV-2 infection are 
reduced in infliximab- treated compared with vedolizumab- 
treated patients.11 We hypothesised that, following at least a 
single dose with BNT162b2 or ChAdOx1 nCoV-19 vaccine, 
serological responses would be similarly impaired in patients 
treated with infliximab compared with vedolizumab arguing 
against delaying second doses in these patients.
Objectives
We aimed to define, in patients with IBD who had received a 
COVID-19 vaccination, whether biological class and concomi-
tant use of an immunomodulator impact:
i. Anti- SARS- CoV-2 spike (S) antibody levels.
ii. Rates of seroconversion.
iii. Antibody responses in patients who had previously been in-
fected with SARS- CoV-2 or who had two doses of vaccine.
METHODS
Patient and settings
ImpaCt of bioLogic therApy on saRs- cov-2 Infection and immu-
niTY (CLARITY) IBD is a UK- wide, multicentre, prospective 
observational cohort study investigating the impact of inflix-
imab and vedolizumab and/or concomitant immunomodu-
lators (azathioprine, mercaptopurine and methotrexate) on 
SARS- CoV-2 acquisition, illness and immunity in patients with 
IBD.
Study methods have been described in detail previously.11 In 
brief, consecutive patients were recruited at the time of atten-
dance at infusion units from 92 National Health Service (NHS) 
hospitals across the UK between 22 September 2020 and 23 
December 2020 (online supplemental pp 2–17). The eligibility 
criteria were age 5 years and over, a diagnosis of IBD, and 
current treatment with infliximab or vedolizumab for 6 weeks 
or more, with at least one dose of drug received in the previous 
16 weeks. Patients were excluded if they had participated in a 
SARS- CoV-2 vaccine trial.
Follow- up visits were timed to coincide with biological infu-
sions and occurred approximately 8 weekly. Here, we report 
vaccine- induced antibody responses at first study visit after 
primary vaccination, and where possible, after two doses. Partic-
ipants were eligible for inclusion in our vaccine immunogenicity 
analysis if they had had a SARS- CoV-2 antibody test within the 
first 10 weeks after their primary vaccination with any of the 
available SARS- CoV-2 vaccines.
Outcome measures
Our primary outcome was anti- SARS- CoV-2 anti- spike (S) 
protein receptor- binding protein antibodies 3–10 weeks after 
primary vaccination.
Secondary outcomes were:
i. The proportion of participants with seroconversion.
Significance of this study
What are the new findings?
 ► Anti- SARS- CoV-2 spike (S) antibody concentrations and rates 
of seroconversion were lower following primary vaccination 
with both the BNT162b2 and ChAdOx1 nCoV-19 vaccines 
in patients with inflammatory bowel disease treated with 
infliximab compared with vedolizumab.
 ► Older age, immunomodulator use, Crohn’s disease (vs 
ulcerative colitis or inflammatory bowel disease unclassified), 
and current smoking were associated with lower anti- SARS- 
CoV-2 antibody concentrations, irrespective of vaccine 
type. Non- white ethnicity was associated with higher anti- 
SARS- CoV-2 (S) antibody concentrations following primary 
vaccination with both vaccines.
 ► Lowest rates of seroconversion were observed in 
participants treated with infliximab in combination with an 
immunomodulator with both the BNT162b2 and ChAdOx1 
nCoV-19 vaccines, whereas highest rates of seroconversion 
were seen in patients treated with vedolizumab monotherapy 
who received either vaccine.
 ► Antibody concentrations and seroconversion rates were 
higher in patients with past SARS- CoV-2 infection prior to 
a single dose of either vaccine, and after two doses of the 
BNT162b2 vaccine.
How might it impact on clinical practice in the foreseeable 
future?
 ► For patients treated with antitumour necrosis factor 
(TNF) therapy, particularly for those also treated with an 
immunomodulator, poor antibody responses to a single dose 
of vaccine exposes them to a potential increased risk of 
SARS- CoV-2 infection.
 ► Higher rates of seroconversion in patients with two 
exposures to SARS- CoV-2 antigen, even in the presence of 
TNF blockade, suggest that all patients receiving anti- TNF 
therapy should be prioritised for optimally timed second 
doses.
 ► Until patients receive a second vaccine dose, they should 
consider that they are not protected from SARS- CoV-2 
infection and continue to practice enhanced physical 
distancing and shielding if appropriate.
 ► Even after two antigen exposures, a small subset of patients 
failed to mount an antibody response. Antibody testing and 
adapted vaccine schedules should be considered to protect 
these at- risk patients.
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ii. Antibody concentrations and rate of seroconversion in pa-
tients with PCR or serological evidence of past SARS- CoV-2 
infection.
iii. Antibody concentrations and seroconversion after two dos-
es of vaccine.
Variables
Variables recorded by participants were demographics (age, sex, 
ethnicity, comorbidities, height and weight, smoking status, and 
postcode), IBD disease activity (PRO2), SARS- CoV-2 symp-
toms aligned to the COVID-19 symptoms study (symptoms, 
previous testing and hospital admissions for COVID-19) and 
vaccine uptake (type and date of primary vaccination). Study 
sites completed data relating to IBD history (age at diagnosis, 
disease duration and phenotype according to the Montreal clas-
sifications, previous surgeries and duration of current biolog-
ical and immunomodulator therapy).11 We linked our data by 
NHS number or Community Health Index to Public Health 
England, Scotland and Wales who archive dates and results of all 
SARS- CoV-2 PCR tests undertaken. Data were entered electron-
ically into a purpose- designed REDCap database hosted at the 
Royal Devon and Exeter NHS Foundation Trust.12 Participants 
without access to the internet or electronic device completed 
their questionnaires on paper case record forms that were subse-
quently entered by local research teams.
Laboratory methods
Laboratory analyses were performed at the Academic Depart-
ment of Blood Sciences at the Royal Devon and Exeter NHS 
Foundation Trust. To determine antibody responses specific to 
vaccination we used the Roche Elecsys Anti- SARS- CoV-2 spike 
(S) immunoassay13 alongside the nucleocapsid (N) immuno-
assay.14 This double sandwich electrochemiluminescence immu-
noassay uses a recombinant protein of the receptor binding 
domain on the spike protein as an antigen for the determination 
of antibodies against SARS- CoV-2. Sample electrochemilumines-
cence signals are compared with an internal calibration curve 
and quantitative values are reported as units (U)/mL.
In- house assay validation experiments demonstrated:
i. The intra- assay and interassay coefficient of variation were 
1.3% and 5.6%, respectively.
ii. Anti- SARS- CoV-2 (S) antibodies were stable in uncentri-
fuged blood and serum at ambient temperature for up to 
7 days permitting postal transport.
iii. No effect was observed on recovery of anti- SARS- CoV-2 (S) 
antibodies following four freeze/thaw cycles.
iv. No analytical interference was observed for the detection of 
anti- SARS- CoV-2 (S) with infliximab or vedolizumab up to 
10 000 mg/L and 60 000 mg/L, respectively, or with antidrug 
antibodies to infliximab or vedolizumab up to 400 AU/mL 
and 38 AU/mL, respectively (data not shown).
At entry to CLARITY IBD and at follow- up visits, all patients 
were tested for previous SARS- CoV-2 infection using the Roche 
Elecsys anti- SARS- CoV-2 (N) immunoassay. Because antibody 
responses are impaired following PCR- confirmed natural infec-
tion we set a threshold of 0.25 times the Cut- Off Index (COI) 
at or above which patients were deemed to have had prior infec-
tion.11 We defined a second threshold of 0.12 times the COI, 
below which patients were deemed to have no evidence of prior 
infection. Patients with a PCR test confirming SARS- CoV-2 
infection at any time prior to vaccination were deemed to have 
evidence of past infection irrespective of any antibody test 
result.
Our threshold for seroconversion was defined at Roche Diag-
nostics (Penzberg, Germany). In brief, anti- SARS- CoV-2 (S) 
antibodies in 534 serum samples from 210 patients (71 hospi-
talised with severe COVID-19 and 139 patients with milder 
disease who were not hospitalised) were correlated with results 
from the cPass SARS- CoV-2 Neutralisation Antibody Detection 
Kit (Genscript, Netherlands), a competitive ELISA that reports 
the proportion of anti- SARS- CoV-2 antibodies that are neutral-
ising.15 While individuals infected with SARS- CoV-2 develop 
binding antibodies to the virus, not all develop neutralising 
antibodies which block cellular infiltration and replication of 
the virus.16 In both cohorts, Elecsys Anti- SARS- CoV-2 spike (S) 
concentrations of greater than or equal to 15 U/mL were asso-
ciated with neutralisation of ≥20% with a positive predictive 
value of 99.10% (95% CI 97.74% to 99.64%) (online supple-
mental figure 1).
Ethical consideration and role of funders
CLARITY IBD is an investigator- led, UK National Institute for 
Health Research COVID-19 urgent public health study, funded 
by the Royal Devon and Exeter NHS Foundation Trust, Hull 
University Teaching Hospital NHS Trust, and by unrestricted 
educational grants from F. Hoffmann- La Roche AG (Switzer-
land), Biogen GmbH (Switzerland), Celltrion Healthcare (South 
Korea), Takeda (UK) and Galapagos NV (Belgium).
None of our funding bodies had any role in study design, data 
collection or analysis, writing, or decision to submit for publica-
tion. Patients were included after providing informed, written 
consent. The sponsor was the Royal Devon and Exeter NHS 
Foundation Trust. The protocol is available online at https://
www. clarityibd. org. The study was registered with the ISRCTN 
registry.
Statistics
The sample size for CLARITY IBD was based on the number of 
participants required to demonstrate a difference in the impact 
of infliximab and vedolizumab on seroprevalence and serocon-
version following SARS- CoV-2 infection, with an estimated 
background seroprevalence of 0.05. We calculated that a sample 
of 6970 patients would provide 80% power to detect differ-
ences in the seroprevalence of anti- SARS- CoV-2 antibodies in 
infliximab- treated patients compared with vedolizumab- treated 
patients, while controlling for immunomodulator status at the 
0.05 significance level. We stored and then analysed all serum 
samples as soon as the Roche Elecsys anti- SARS- CoV-2 (S) 
immunoassay was established in our laboratory.
Statistical analyses were undertaken in R V.4.0.4 (R Founda-
tion for Statistical Computing, Vienna, Austria). All tests were 
two tailed and values of p<0.05 were considered significant. We 
included patients with missing clinical data in analyses for which 
they had data and have specified the denominator for each vari-
able. Anti- S antibody concentrations are reported as geometric 
means and SD. Other continuous data are reported as median 
and IQR, and discrete data as numbers and percentages, unless 
otherwise stated.
Univariable analyses, using t- tests of log- transformed anti- 
SARS- CoV-2 (S) antibody concentration and Spearman’s rank 
correlation coefficients, were used to identify demographic, 
disease, vaccine, and treatment- related factors associated with 
the concentration of anti- SARS- CoV-2 (S) antibodies. To test 
our primary outcome, we used multivariable linear regression 
models to identify factors independently associated with log 
anti- SARS- CoV-2 (S) levels. A priori, we included age, ethnicity, 
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biological medication and immunomodulator use. No stepwise 
regression was performed. Results are presented after expo-
nentiation, so that the coefficients of the model correspond 
to the fold change (FC) associated with each binary covariate. 
For age, a cut- off was chosen based on graphical inspection of 
the relationship between age and anti- SARS- CoV-2 (S) anti-
body concentrations. We also report the proportions of patients 
who seroconverted following vaccination. Seroconversion was 
defined as a threshold of 15 U/mL. We conducted sensitivity 
analyses to compare antibody responses stratified by participants 
with serological or PCR evidence of SARS- CoV-2 infection at 




Between September 22 2020 and December 23 2020, 7226 
patients were recruited to the CLARITY study from 92 UK 
hospitals.11 For the primary immunogenicity analyses we 
included 865 infliximab- treated and 428 vedolizumab- 
treated participants without evidence of prior SARS- CoV-2 
infection, who had received uninterrupted biological therapy 
since recruitment and had an antibody test between 21 and 
70 days after primary vaccination. Participant characteristics 
are shown in table 1.
Anti-SARS-CoV-2 (S) antibody level following primary 
COVID-19 vaccine
Geometric mean (geometric SD) anti- SARS- CoV-2 (S) anti-
body concentrations were lower in patients treated with 
infliximab than vedolizumab, following both the BNT162b2 
(6.0 U/mL (5.9) vs 28.8 U/mL (5.4) p<0.0001) and ChAdOx1 
nCoV-19 (4.7 U/mL (4.9) vs 13.8 U/mL (5.9) p<0.0001) 
vaccines (figure 1). Among infliximab- treated patients, the 
geometric mean (geometric SD) anti- SARS- CoV-2 (S) anti-
body concentrations were also lower in patients treated with 
a concomitant immunomodulator. Additional univariable 
analyses are shown in table 2.
In our multivariable models, anti- SARS- CoV-2 antibody 
concentrations were lower in infliximab- treated patients 
compared with vedolizumab- treated patients in participants 
who received the BNT162b2 (FC 0.29 (95% CI 0.21 to 0.40), 
p<0.0001) and ChAdOx1 nCoV-19 (FC 0.39 (95% CI 0.30 to 
0.51), p<0.0001) vaccines. Age ≥60 years, immunomodulator 
Table 1 Baseline characteristics of participants who had anti- SARS- CoV-2 spike antibodies measured 3–10 weeks following primary vaccination 
against SARS- CoV-2
Variable Infliximab Vedolizumab Overall P value
Vaccine BNT162b2 44.7% (387/865) 47.2% (202/428) 45.6% (589/1293) 0.41
ChAdOx1 nCoV-19 55.3% (478/865) 52.8% (226/428) 54.4% (704/1293)
Age (years) 41.4 (31.5–54.8) 49.6 (37.1–63.8) 43.8 (32.8–57.6) <0.0001
Sex Female 50.3% (434/863) 47.1% (200/425) 49.2% (634/1288) 0.19
Male 49.7% (429/863) 52.7% (224/425) 50.7% (653/1288)
Intersex 0.0% (0/863) 0.0% (0/425) 0.0% (0/1288)
Prefer not to say 0.0% (0/863) 0.2% (1/425) 0.1% (1/1288)
Ethnicity White 91.8% (791/862) 89.9% (381/424) 91.1% (1172/1286) 0.62
Asian 5.3% (46/862) 7.5% (32/424) 6.1% (78/1286)
Mixed 1.9% (16/862) 1.9% (8/424) 1.9% (24/1286)
Black 0.7% (6/862) 0.5% (2/424) 0.6% (8/1286)
Other 0.3% (3/862) 0.2% (1/424) 0.3% (4/1286)
Diagnosis Crohn’s disease 65.4% (566/865) 40.7% (174/428) 57.2% (740/1293) 0.00050
Ulcerative colitis or IBD unclassified 34.6% (299/865) 59.3% (254/428) 42.8% (553/1293)
Duration of IBD (years) 8.0 (4.0–16.0) 10.0 (5.0–17.8) 9.0 (4.0–16.0) 0.0040
Age at IBD diagnosis (years) 28.8 (21.6–41.8) 34.0 (23.3–47.6) 30.3 (21.9–43.7) <0.0001
Immunomodulator 61.6% (533/865) 22.0% (94/427) 48.5% (627/1292) <0.0001
5- ASA 23.0% (199/865) 31.6% (135/427) 25.9% (334/1292) 0.0012
Steroids 3.0% (26/865) 8.4% (36/427) 4.8% (62/1292) <0.0001
BMI (kg/m2) 25.9 (22.8–30.6) 26.1 (23.1–30.1) 26.0 (22.9–30.4) 0.75
Heart disease 3.6% (31/865) 6.5% (28/428) 4.6% (59/1293) 0.023
Diabetes 3.8% (33/865) 7.5% (32/428) 5.0% (65/1293) 0.0065
Lung disease 13.5% (117/865) 18.2% (78/428) 15.1% (195/1293) 0.032
Kidney disease 1.2% (10/865) 2.1% (9/428) 1.5% (19/1293) 0.22
Cancer 0.5% (4/865) 2.1% (9/428) 1.0% (13/1293) 0.013
Smoker Yes 9.7% (84/862) 5.4% (23/425) 8.3% (107/1287) 0.0010
Not currently 32.0% (276/862) 41.6% (177/425) 35.2% (453/1287)
Never 58.2% (502/862) 52.9% (225/425) 56.5% (727/1287)
Exposure to documented cases of COVID-19 9.4% (81/862) 8.7% (37/425) 9.2% (118/1287) 0.76
Income deprivation score 0.086 (0.052–0.151) 0.084 (0.054–0.141) 0.086 (0.052–0.147) 0.94
Active disease (PRO2) 4.9% (41/831) 11.4% (46/405) 7.0% (87/1236) <0.0001
Values presented are median (interquartile range) or percentage (numerator/denominator). P values represent the results of a Mann Whitney U, Kruskal Wallis or Fisher’s exact 
test.
5- ASA, 5- aminosalicylic acid; BMI, body mass index; IBD, inflammatory bowel disease; ; PRO2, IBD disease activity.
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use and current smoking were also independently associated with 
lower anti- SARS- CoV-2 antibody concentrations in participants 
who received either vaccine. Conversely, non- white ethnicity 
was associated with higher antibody concentrations following 
both vaccines (figure 2).
To allow us to calculate a 15- day rolling geometric mean of 
anti- SARS- CoV-2 antibody concentrations, we included 2126 
participants who had an antibody test carried out between 
1 and 63 days after primary vaccination (1427 treated with 
infliximab and 699 treated with vedolizumab), as shown in 
figure 3. Three weeks after vaccination, we observed lower 
anti- SARS- CoV-2 (S) antibody concentrations in infliximab- 
treated patients compared with vedolizumab- treated patients 
following both vaccines. Sustained serological responses 
were observed in the vedolizumab- treated patients but not 
infliximab- treated patients.
Seroconversion following primary COVID-19 vaccination
The lowest rates of seroconversion were observed in participants 
treated with infliximab in combination with an immunomodu-
lator with both the BNT162b2 (27.1%; 65/240) or ChAdOx1 
nCoV-19 (20.2%; 60/297) vaccines. Highest rates of serocon-
version were seen in patients treated with vedolizumab mono-
therapy who received the BNT162b2 (74.7%;124/166) or 
ChAdOx1 nCoV-19 (57.3%; 94/164) vaccines (figure 4).
Antibody responses following prior SARS-CoV-2 infection
Among participants with SARS- CoV-2 infection prior to 
vaccination, geometric mean (SD) anti- SARS- CoV-2 (S) anti-
body concentrations were lower in infliximab- treated patients 
compared with vedolizumab- treated patients in those who 
received a single dose of BNT162b2 (191 U/mL (12.5) vs 1865 U/
mL (8.0) p<0.0001) and ChAdOx1 nCoV-19 (185 U/mL (9.3) 
vs 752 (12.5) p=0.046) vaccines. In both infliximab- treated 
patients and vedolizumab- treated patients, antibody concentra-
tions following vaccination were higher than those observed in 
patients without prior infection (figure 5). Overall, across both 
vaccines, 81.7% (76/93) patients treated with infliximab and 
97.1% (33/34) patients treated with vedolizumab seroconverted 
(p=0.041).
Antibody responses following two COVID-19 vaccine doses
Antibody responses were assessed in 27 patients following two 
doses of the BNT162b2 vaccine without serological evidence of 
prior infection (figure 5). In both infliximab- and vedolizumab- 
treated patients, antibody levels and seroconversion rates were 
higher after two doses than after a primary vaccine without prior 
infection (geometric means infliximab 158 U/mL (7.0) vs 6.0 U/
mL (5.9), p<0.0001; vedolizumab 562 U/mL (11.5) vs 28.8 U/
mL (5.4), p=0.018). After second- vaccine doses, 85% (17/20) 
infliximab- treated patients and 86% (6/7) vedolizumab- treated 
patients seroconverted (p=0.68).
DISCUSSION
We have shown that anti- SARS- CoV-2 spike antibody levels and 
rates of seroconversion are lower following vaccination with a 
single dose of either BNT162b2 or ChAdOx1 nCoV-19 vaccines 
in patients with IBD treated with infliximab than vedolizumab. 
Combination therapy with an immunomodulator further atten-
uated immunogenicity to both vaccines in infliximab- treated 
patients. Reassuringly, however, a second exposure to antigen, 
either by vaccination after infection, or a second dose of vaccine 
led to seroconversion in most patients.
Direct comparisons between our data and the antibody 
responses reported in the vaccine registration trials are limited by 
differences in the assays used to define immunogenicity and the 
adoption of different thresholds to define seroconversion. No 
adequately powered studies have reported the effect of anti- TNF 
drugs on vaccine responses.17 Our findings are similar, however, 
to recent reports of the immunogenicity of the BNT162b2 and 
mRNA-1273 vaccines in transplant recipients and in patients 
with malignancy treated with antimetabolite immunosuppres-
sion, conventional chemotherapy or immune checkpoint inhibi-
tors.18 19 The authors showed fewer patients treated with potent 
immunosuppressants seroconverted than healthy controls. 
Importantly, as we have also shown here, second vaccine doses 
led to seroconversion in the cancer cohort. However, even after 
two antigen exposures, a small subset of patients (18% (20/113) 
infliximab- treated patients and 5% (2/41) vedolizumab- treated 
patients) in our study failed to mount an antibody response. To 
identify this group, and because the sustainability of antibody 
responses overall is unknown, serial measurement of antibody 
responses is indicated.
Urgent research is needed to understand the factors linked to 
non- response and how to potentiate long- term immunogenicity 
in this group. Strategies to be tested include the manipulation 
of timing of second vaccinations, booster doses, the use of adju-
vants and/or switching between vaccines with different mecha-
nisms of action. Moreover, from the public health standpoint, 
recent case reports have shown that potent immunosuppres-
sion leads to chronic nasopharyngeal carriage and evolution of 
new SARS- CoV-2 variants.20 21 Whether this occurs in patients 
treated with anti- TNF therapy with impaired antibody response 
is an important conceptual concern.
Our data have other important findings relating to 
SARS- CoV-2 vaccine responses. We have demonstrated that 
antibody responses to SARS- CoV-2 vaccines are reduced in 
older individuals and current smokers. Smoking has also been 
associated with lower antibody responses to hepatitis B vacci-
nation and faster decay of antibodies after vaccination with live 
attenuated and trivalent influenza vaccines.22 23 We have also 
demonstrated higher antibody responses to both the BNT162b2 
and ChAdOx1 nCoV-19 vaccines in non- white participants. This 
might be explained by differences in genetics,24 gut microbiota,25 
Figure 1 Anti- SARS- CoV-2 spike antibody concentration stratified 
by biological therapy (infliximab vs vedolizumab) and type of vaccine. 
The wider bar represents the geometric mean, while the narrower bars 
are drawn one geometric SD either side of the geometric mean. The 
threshold shown of 15 U/mL was used to determine seroconversion.
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nutrition26 and priming of the immune system by prior exposure 
to SARS- CoV-2 not detected by our prevaccination antibody test. 
Lower antibody concentrations were also observed in patients 
with Crohn’s disease when compared with patients with UC or 
IBD unclassified. Despite evidence of defective mucosal immu-
nity, previous vaccine studies involving patients with Crohn’s 
disease or UC have not shown attenuated antibody responses to 
vaccination in the absence of concomitant immunomodulator or 
biological therapy.6 7
The cytokine TNF shapes multiple aspects of host immune 
responses, including T- cell dependent antibody production. 
Genetic ablation of TNF results in disruption of B- cell follicles 
in germinal centres with defective induction of antigen- induced 
antibody production.27 28 These biological properties may in part 
explain why TNF blockade is clinically beneficial in IMIDs, but 
also explain the increased risk of serious and opportunistic infec-
tions and impaired response to other vaccines.
Our findings have important implications for patients treated 
with anti- TNF drugs particularly those also treated with an 
immunomodulator. Poor antibody responses to a single dose 
of vaccine unnecessarily exposes infliximab- treated patients to 
SARS- CoV-2 infection. However, because we observed higher 
rates of seroconversion in patients with two exposures to 
SARS- CoV-2 antigen, even in the presence of TNF blockade, 
Table 2 Univariable associations with anti- SARS- CoV-2 spike antibodies, stratified by vaccine type
Variable
BNT162b2 ChAdOx1 nCoV-19
Value P value Value P value
Biological treatment Infliximab 6.0 (5.9) <0.0001 4.7 (4.9) <0.0001
Vedolizumab 28.8 (5.4) 13.8 (5.9)
Immunomodulator in infliximab- treated participants No 9.7 (4.7) <0.0001 5.7 (5.1) 0.045
Yes 4.4 (6.3) 4.2 (4.7)
Immunomodulator in vedolizumab- treated participants No 32.4 (5.2) 0.052 15.6 (6.0) 0.082
Yes 16.7 (6.3) 10.0 (5.5)
Age (years) rho=−0.22 <0.0001 rho=−0.15 <0.0001
Sex Female 9.4 (7.0) 0.092 6.6 (5.5) 0.83
Male 10.9 (6.3) 6.8 (5.7)
Ethnicity White 9.4 (6.6) 0.037 6.2 (5.6) 0.0051
Asian 20.9 (7.3) 16.1 (5.2)
Mixed 25.7 (6.7) 13.7 (5.3)
Black 12.5 (1.6) 19.4 (2.2)
Other 22.9 (3.7) 5.7 (3.1)
Diagnosis Crohn’s disease 7.3 (6.4) <0.0001 5.6 (5.6) 0.0014
Ulcerative colitis or IBD- 
unclassified
15.6 (6.5) 8.5 (5.5)
Duration of IBD (years) rho=−0.16 <0.0001 rho=−0.12 0.0013
Age at IBD diagnosis (years) rho=−0.13 0.0021 rho=−0.04 0.25
5- ASA No 9.8 (6.6) 0.40 6.7 (5.5) 0.93
Yes 11.5 (7.1) 6.6 (5.9)
Steroids No 10.2 (6.7) 0.90 6.8 (5.5) 0.12
Yes 10.7 (7.3) 4.1 (6.7)
BMI (kg/m2) rho=−0.08 0.068 rho=−0.01 0.81
Heart disease No 10.3 (6.7) 0.65 6.9 (5.6) 0.010
Yes 8.7 (7.0) 2.8 (5.2)
Diabetes No 10.7 (6.7) 0.0028 6.8 (5.6) 0.066
Yes 4.1 (4.6) 4.0 (5.2)
Lung disease No 10.1 (6.9) 0.70 6.9 (5.5) 0.31
Yes 10.9 (5.7) 5.7 (6.1)
Kidney disease No 10.2 (6.6) 0.60 6.7 (5.5) 0.66
Yes 15.6 (10.4) 4.7 (12.4)
Cancer No 10.4 (6.6) 0.13 6.7 (5.6) 0.069
Yes 2.0 (9.2) 2.3 (3.6)
Smoking Yes 4.7 (7.1) 0.0077 3.4 (4.8) 0.00077
Not currently 9.4 (6.6) 6.1 (5.4)
Never 11.8 (6.5) 8.0 (5.7)
Exposure to documented cases of COVID-19 No 10.3 (6.7) 0.87 6.6 (5.5) 0.53
Yes 9.8 (6.8) 7.8 (6.1)
Income deprivation score rho=0.01 0.75 rho=0.02 0.65
Active disease (PRO2) No 10.1 (6.5) 0.32 6.6 (5.4) 0.51
Yes 14.0 (7.6) 8.1 (7.0)
Values presented are geometric mean antibody concentration (geometric SD) or Spearman’s rho. P values represent the results of an unpaired t- test or test of Spearman’s rho.
5- ASA, 5- aminosalicylic acid; BMI, body mass index; IBD, inflammatory bowel disease; VAS, Visual Analogue Scale.
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these patients should be prioritised for optimally timed second 
doses. Until patients receive a second vaccine dose they should 
consider that they are not protected from SARS- CoV-2 infec-
tion and continue to practice enhanced physical distancing and 
shielding if appropriate.
Limitations
While our data are biologically plausible, we acknowledge the 
following limitations of our study. We have used an electrochem-
iluminescence immunoassay to measure antibody concentrations 
rather than using a neutralising assay. Although neutralisation 
assays are considered more biologically relevant, it is now estab-
lished that anti receptor- binding domain antibodies, which target 
the spike protein component that engages host cells through liga-
tion of ACE 2, closely correlate with neutralisation assays.29 30 
Our validation experiments, comparing anti- SARS- CoV-2 spike 
(S) concentrations with neutralisation using the cPass test in two 
cohorts of patients with PCR confirmed SARS- CoV-2 infection, 
confirm this correlation. Second, we only assessed humoral 
responses to infection, and it is likely that protective immunity 
additionally requires induction of memory T cell responses. 
Third, we were unable to investigate whether the timing of 
biological infusion with respect to vaccination or drug level at the 
time of vaccination, influences antibody responses. As follow- up 
blood tests occurred at the time of infusions, which for the vast 
majority occurred 8 weekly, the time from last infusion to vacci-
nation was negatively correlated with the time from vaccination 
to the next antibody test, confounding these analyses. Finally, 
we investigated one anti- TNF drug, infliximab, only. However, 
we suspect that our key findings will apply to other anti- TNF 
biologics used to treat IMIDs, including adalimumab, certoli-
zumab, golimumab and etanercept. Further observational data 
will be required to elucidate the impact of other classes of thera-
pies for IMIDs on SARS- CoV-2 vaccine immunogenicity.
CONCLUSIONS
Infliximab is associated with attenuated immunogenicity 
to a single dose of the BNT162b2 and ChAdOx1 nCoV-19 
SARS- CoV-2 vaccines in patients with IBD. Immunomodulators 
further blunted immunogenicity rates to both vaccines. Reassur-
ingly, vaccination after infection, or a second dose of vaccine 
Figure 2 Exponentiated coefficients of linear regression models of 
log(anti- SARS- CoV-2 spike antibody concentration). The resultant values 
represent the fold change of antibody concentration associated with 
each variable. Each vaccine was modelled separately, and then a further 
model was created using all of the available data. IBDU, inflammatory 
bowel disease unclassified; UC, ulcerative colitis.
Figure 3 Rolling geometric mean antibody concentration over time, 
stratified by biological therapy (infliximab vs vedolizumab) and vaccine. 
Geometric means are calculated using a rolling 15- day window (ie, 
7 days either side of the day indicated). The shaded areas represent the 
95% CIs of the geometric means. Overall, data from 2126 participants 
(1427 on infliximab and 699 on vedolizumab) between 1 and 63 days 
post vaccination are included in this graph .
Figure 4 Percentages of participants with seroconversion defined by 
an anti- SARS- CoV-2 spike antibody concentration ≥15 U/mL, stratified 
by vaccine, biological and immunomodulator use. Error bars represent 
the 95% CI of the percentages. IMM, immunomodulator.
Figure 5 Anti- SARS- CoV-2 spike antibody concentration, stratified 
by biological therapy (infliximab vs vedolizumab), prior infection and 
number of doses and type of vaccine. The wider bar represents the 
geometric mean, while the narrower bars are drawn one geometric SD 
either side of the geometric mean. The threshold shown of 15 U/mL is 
the one used to determine seroconversion.
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led to seroconversion in most patients. Delayed second dosing 
should be avoided in patients treated with infliximab.
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